imageSlide
Lilly insulin access programs
60px
medium
Obese man looking in the mirror
white
Our medicines
link
our medicines
spacer
large
spacer
large
Insulin Program
$35 is the most people living with diabetes who rely on Lilly insulin should have to pay.
60px
20px
spacer
large
spacer
small
spacer
small
Support for affordable
insulin solutions
60px
variation-2
People who rely on insulin to manage diabetes care deserve affordable access, but systemic barriers stand in the way. Through significant investments in research and solutions that offer more affordable options, we’re working to help.
In 2020, we launched the Lilly Insulin Value Program—allowing anyone eligible to purchase their monthly prescription of Lilly insulin for $35 or less. Now, we’re announcing updates that make accessing $35-a-month* Lilly insulin even easier, including:
In 2020, we launched the Lilly Insulin Value Program—allowing anyone eligible to purchase their monthly prescription of Lilly insulin for $35 or less. Now, we’re announcing updates that make accessing $35-a-month* Lilly insulin even easier, including:
20px
01
36px
An automatic $35 max out-of-pocket monthly cost for people with commercial insurance at the majority of retail pharmacies
20px
02
36px
An easy-to-download savings card that provides a $35 max out-of-pocket monthly cost for people who are uninsured, or need to use a non-participating retail pharmacy
20px
Those who need a savings card can visit our Insulin Value Program site, answer two questions, and immediately download it.
Beyond the changes listed above, we've also made significant price reductions to our branded and non-branded insulins.
Beyond the changes listed above, we've also made significant price reductions to our branded and non-branded insulins.
20px
*Terms and conditions apply. Automatically applied at the majority of retail pharmacies for those with commercial insurance. Government restrictions exclude people enrolled in federal government insurance programs from Lilly's $35 solutions. But federal law provides that Medicare Part D beneficiaries also pay no more than $35 per month for insulin.
20px
spacer
large
spacer
small
spacer
small
spacer
large
spacer
large
spacer
large
Continued innovation to
improve diabetes care
48px
spacer
small
spacer
large
spacer
large
spacer
large
No one should have to make trade-offs when it comes to health. For over 100 years, we’ve been focused on addressing the impact of diabetes and improving the lives of people managing the disease. In our recent history, we’ve introduced options that are widely used and have helped with insulin health care costs:
20px
spacer
small
2016
top
In 2016, we launched the first follow-on biologic insulin in the U.S.
16px
2019
top
In 2019, we introduced our non-branded version of our most popular insulin at a list price 50% lower than its branded counterpart and then lowered the price by an additional 40% in 2022
16px
2020
top
In 2020, we created the Lilly Insulin Value Program, enabling the uninsured and commercially insured access to $35 Lilly insulin
16px
2021
top
In 2021, we committed all our insulins to the Medicare Part D Savings Model, expanding $35 access even further
16px
spacer
small
But our work to find better ways to support people living with diabetes goes beyond insulin pricing. We’re constantly in search of the next scientific breakthrough—the innovation that will uncover new and better treatments or even, one day, eliminate this disease.
20px
spacer
small
imageSlide
Our portfolio of current medicines
100px
Ringside
We're constantly working to advance the next great breakthrough. Take a look at all our current medicines, including those for diabetes.
20px
Scientist smiling in lab
Our medicines
link
Visit our portfolio of current medicines
image
Insulin access is an urgent need worldwide
48px
Many people with diabetes who live in low- and middle-income countries lack care due to gaps in healthcare and infrastructure. We’re working to improve access on a global scale through additional solutions and partnerships.
16px
Learn about our work
link
Learn about our work in medicine access